Literature DB >> 26101172

A mechanism for mineralocortcoid participation in renal disease and heart failure.

Richard N Re1.   

Abstract

Various forms of chronic renal disease as well as congestive heart failure progress irrespective of currently available supportive care. Clinical evidence indicates that blockade of the renin-angiotensin system and/or mineralocorticoid inhibition are partially effective. Recently, it was suggested that the initiation of feed-forward intracrine loops such as renin-angiotensin system up-regulation can explain the progression of disease in the face of the control of initiating factors such as high glucose or hypertension. Here, these notions are expanded to include a potential interaction of mineralocorticoid activity with intracrine renin-angiotensin system up-regulation. In addition to suggesting therapeutic interventions, these observations lead to an expanded view of intracrine physiology.
Copyright © 2015 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aldosterone; angiotensin; intracrine

Mesh:

Substances:

Year:  2015        PMID: 26101172     DOI: 10.1016/j.jash.2015.05.002

Source DB:  PubMed          Journal:  J Am Soc Hypertens        ISSN: 1878-7436


  3 in total

Review 1.  Age-Related Macular Degeneration and Intracrine Biology: An Hypothesis.

Authors:  Richard N Re
Journal:  Ochsner J       Date:  2016

Review 2.  Intracrine angiotensin II functions originate from noncanonical pathways in the human heart.

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Jasmina Varagic; Che Ping Cheng; Leanne Groban; Hao Wang; James F Collawn; Louis J Dell Italia
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-05-27       Impact factor: 4.733

Review 3.  The Unappreciated Role of Extrarenal and Gut Sensors in Modulating Renal Potassium Handling: Implications for Diagnosis of Dyskalemias and Interpreting Clinical Trials.

Authors:  Murray Epstein; Meyer D Lifschitz
Journal:  Kidney Int Rep       Date:  2016-04-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.